MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Exact Sciences Corporation Interest Expense 2011-2025 | EXAS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Exact Sciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 18.6 M | 67.9 M | 199 M | 36.8 M | 206 K | -213 K | 6 K | 51 K | 69 K | 41 K | 21 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | -213 K | 29.3 M |
Quarterly Interest Expense Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -9.61 M | 111 K | -7.94 M | - | -7.87 M | -7.82 M | 4.11 M | - | -5.24 M | -4.51 M | -4.48 M | - | -4.68 M | -4.65 M | -4.62 M | - | 23.6 M | 22.9 M | 25.2 M | -13.7 M | 13.2 M | 12.7 M | 22 M | -11 M | 10.7 M | 8.6 M | -6.51 M | -51 K | -51 K | -54 K | -50 K | -52 K | -54 K | -53 K | 54 K | -62 K | -40 K | 107 K | 11 K | 11 K | 12 K | 13 K | 15 K | 16 K | 16 K | 18 K | 19 K | 20 K | 11 K | 5 K | 5 K | 6 K | 5 K | 5 K | 5 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.2 M | -13.7 M | 988 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 20.97 | -1.38 % | $ 226 M |  China |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 0.23 | -4.4 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 39.53 | -1.4 % | $ 1.1 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.52 | - | $ 1.93 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.17 | 1.29 % | $ 289 M |  Israel |
 |
DexCom
DXCM
|
20.3 M | $ 67.51 | 0.13 % | $ 26.1 B | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 230.0 | -0.45 % | $ 168 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 26.78 | -0.85 % | $ 810 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 19.47 | -1.32 % | $ 1.05 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 101.9 | -0.7 % | $ 4.02 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.21 | -6.25 % | $ 102 K | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 226.52 | 0.26 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 103.35 | 0.94 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.44 | -1.68 % | $ 583 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 135.12 | -0.15 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 203.88 | - | $ 10.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.94 | -3.14 % | $ 2.65 M | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 7.12 | -0.35 % | $ 1.54 B | USA |
 |
National Research Corporation
NRC
|
862 K | $ 18.74 | 0.46 % | $ 460 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 176.16 | 0.15 % | $ 19.6 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 6.76 | -0.88 % | $ 877 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 254.32 | 0.02 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 182.75 | -0.51 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 688.22 | 0.01 % | $ 56.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.3 M | $ 1.77 | -5.85 % | $ 449 M | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 66.73 | 0.07 % | $ 4.62 B | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 419.64 | 0.11 % | $ 30.1 B |  Schweiz |
 |
Agilent Technologies
A
|
81 M | $ 138.31 | 0.03 % | $ 42 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.7 | 1.9 % | $ 6.2 M | USA |
 |
Bioventus
BVS
|
1.29 M | $ 7.4 | 0.27 % | $ 464 M | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 12.33 | 0.2 % | $ 1.56 B | USA |